肝细胞癌细胞粘弹性的改变及细胞骨架干扰剂的影响

目的 从细胞骨架角度探讨肝癌细胞粘弹性改变的基础，及细胞骨架结构干扰剂对其改变的影响方法采用微管吸吮技术测定正常肝细胞的粘弹性，三参数标准线性固体模型拟合实验结果。结果 肝癌细胞的弹性系数较肝细胞增高，秋水仙素、长春花碱使癌细胞粘弹性系数与肝细胞相比呈现不同的效应方式和强度，细胞松驰素Ｄ则使２种细胞弹性系数均呈现相似的显著下降趋势。结论 细胞骨架结构的完整性是维持肝细胞和肝癌细胞粘弹性及被动变形机     

Purpura fulminans: a case series managed at a regional burn center.

Purpura fulminans (PF) is a protein C deficiency disease process with a high case fatality rate; however, overall incidence of the disease remains relatively very low. The similarity between skin necrosis secondary to PF and full-thickness skin burns provides the rationale for treating PF case in a burn center. In this case series we reviewed our experiences in managing PF and their associated favorable outcomes. Retrospective chart review of five PF cases managed between September 2004 and August 2006 at our Burn Center with 100% survival. Management of cases following the standard care of the Burn Center for a full-thickness burn included antibiotics, fluid resuscitation, surgical debridement with skin grafting, and activated protein C (Drotrecogin alfa) replacement. Two patients required amputations of extremities and all had surgical debridement. One required hemodialysis and two needed both hemodialysis and positive-pressure mechanical ventilator. No patient experienced any bleeding complications during or after surgery while receiving activated protein C. Early diagnosis and treatment at a burn center may reduce mortality and morbidity and loss of extremities in PF cases.     

VEGF在下腔静脉隔膜型布-加综合征患者中异常表达的意义分析

目的探讨下腔静脉膜性阻塞型布-加综合征（Budd-Chiari syndrome,BCS）患者血管内皮损伤在隔膜形成过程中发挥的作用;方法采用酶联免疫吸附法（Enzyme-linked immunosorbent assay,ELISA）检测下腔静脉膜性阻塞（Membranous obstruction of inferior vena cava,MOVC）患者下腔静脉血液中VEGF的含量,并与非BCS对照组对比进行统计学分析;结果 MOVC患者下腔静脉血液中VEGF明显高于非BCS对照组,差异有统计学意义（P〈0.001）;结论血管内皮损伤是下腔静脉隔膜形成的激发因素之一。     

Association of common PALB2 polymorphisms with breast cancer risk: a case-control study

PURPOSE: The PALB2 gene has an essential role in BRCA2-mediated DNA double-strand break repair and intra-S phase DNA damage checkpoint control, and its mutations are moderately associated with breast cancer susceptibility. This study was designed to investigate the common variants of PALB2 and their association with breast cancer risk. EXPERIMENTAL DESIGN: Four single nucleotide polymorphisms (SNP; rs249954, rs249935, rs120963, and rs16940342) which tagged all 19 of the reported SNPs (minor allele frequency >0.05) covering PALB2 were selected and genotyped in 1,049 patients with breast cancer and 1,073 cancer-free controls in a female Chinese population. RESULTS: Based on the multiple hypothesis testing with the Benjamini-Hochberg method, tagging SNPs (tSNP) rs249954, rs120963, and rs16940342 were found to be associated with an increase of breast cancer risk (false discovery rate-adjusted P values of 0.004, 0.028, and 0.049, respectively) under the dominant model. tSNP rs249954 was associated with a 36% increase of breast cancer risk [adjusted odds ratio (OR), 1.36; 95% confidence intervals (CI), 1.13-1.64; P = 0.001; TT/TC versus CC genotypes]. The adjusted OR for rs120963 was 1.25 (95% CI, 1.04-1.49; P = 0.014; CC/CT versus TT genotypes). For rs16940342, the adjusted OR was 1.21 (95% CI, 1.02-1.45; P = 0.037; GG/GA versus AA genotypes). Based on an additive model, tSNPs rs249954 and rs120963 were associated with an increase of breast cancer risk (P = 0.005 and 0.019; respectively), with the false discovery rate-adjusted P values being 0.020 and 0.038, respectively. CONCLUSIONS: Our data suggest that the variants of PALB2 confer low-penetrance breast cancer susceptibility in a Chinese population.     

肝动脉化疗栓塞加门静脉灌输CD3AK细胞治疗转移性肝癌的研究

目的：观察肝动脉化疗栓塞＋门静脉插管化疗、灌输ＣＤ３ＡＫ细胞治疗转移性肝癌的临床疗效及对机体免疫功能的影响。方法：将２５例大肠癌肝转移患者随机分为Ａ，Ｂ两组，Ａ组行肝动脉化疗栓塞＋门静脉插管化疗、灌输ＣＤ３ＡＫ细胞治疗，Ｂ组行肝动脉化疗栓塞＋门静及脉插管化疗治疗。结果：Ａ组患者的细胞免疫指标在术后迅速恢复且维持在高水平状态，避免了机体由于手术打击而导致术后免疫力普遍降低的现象，而Ｂ组术后细胞免疫功     

A meta-analysis of chemotherapy regimen Fluorouracil/Leucovorin/Oxaliplatin Compared with Fluorouracil/Leucovorin in treating advanced colorectal cancer

BackgroundWe performed a meta-analysis to evaluate the efficacy and safety of Fluorouracil (FU)/Leucovorin (LV)/Oxaliplatin compared to FU/LV in treating advanced colorectal cancer.MethodsTwo independent researchers identified and extracted all relevant literature using MEDLINE and the Cochrane Library Database. The regimens included arm A (FU/LV) and arm B (FU/LV/Oxaliplatin) with no other chemotherapy agent.ResultsFive randomized controlled trials (RCTs) fulfilled the requirements. All RCTs showed superiority of FU/LV/Oxaliplatin to FU/LV when measuring RR (response rate) and PFS (progression-free survival); no significant improvement in OS (overall survival) was observed. This meta-analysis shows a better RR for the FU/LV/Oxaliplatin group (OR 4.02, 95% CI 2.37–6.82, p < 0.00001). The incidence of grade 3/4 toxicities, including neutropenia, thrombocytopenia, vomiting, neurological toxicity, toxicity-related dose modification and discontinuation was higher in the FU/LV/Oxaliplatin group, while the incidence of anemia, nausea and diarrhea was not different.ConclusionFU/LV/Oxaliplatin offers better efficacy (RR and PFS) than FU/LV in the treatment of advanced colorectal cancer. The incidence of grade 3/4 toxicities, i.e. neutropenia, thrombocytopenia, vomiting, neurological toxicity, is significantly higher in the FU/LV/Oxaliplatin than in the FU/LV group but these are manageable or reversible.